Monday May 13, 2013 0 commentsDENVER - TYRX Inc. said its AIGISRx Antibacterial Envelope significantly reduced device infection rates in patients at high risk for device infection who received cardiovascular implantable device (CIED) implants, according to a study it presented at Heart Rhythm 2013 in Denver.
TYRX said researchers from the Arrhythmia Institute, Valley Health System and Columbia University College of Physicians and Surgeons conducted a study of infections in 275 patients who received a CIED with the envelope and the same number who received a CIED without the antibacterial envelope.
TYRX said the study found use of the antibacterial envelope was associated with a 70 percent reduction in CIED infections in patients at high risk of device infection.
The study also found there were "significantly fewer" CIED infections in those patients with the envelope compared to those without it.
"The burden of CIED infections is increasing over time and is associated with significant morbidity and mortality, along with prolonged hospital stays and high costs," said Dr. Suneet Mittal, who led the study.
"Our data suggest that the AIGISRx Antibacterial Envelope has an important role in high-risk patients undergoing a CIED procedure."
The study was funded by a research grant from TYRX. For more information, visit www.TYRX.com or www.HeartDeviceInfection.com.